World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
29678
World Ranking
16950
National Ranking
8500

Angelo Di Leo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Angelo Di Leo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 316 publications — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Angelo Di Leo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Angelo Di Leo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Angelo Di Leo was affiliated with the Academy for Urban School Leadership in the United States and contributed extensively to the fields of Medicine and Biochemistry, Genetics and Molecular Biology throughout their career. Their work prominently focused on Oncology, Cancer Research, and Pulmonary and Respiratory Medicine, with further specialization in Molecular Biology and Genetics.

The main topics covered in Angelo Di Leo's research included:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics
  • Cancer Treatment and Pharmacology
  • Cancer-related Molecular Pathways
  • Monoclonal and Polyclonal Antibodies Research

Angelo Di Leo published in several reputable venues, with frequent contributions to:

  • Cancer Research (6 publications)
  • Annals of Oncology (5 publications)
  • Cancers (3 publications)
  • The Lancet (2 publications)
  • Clinical Cancer Research (2 publications)

Some of Angelo Di Leo's recent research papers included:

  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology
  • Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative, 2021, Cancer Discovery
  • Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,800 women from 86 randomised trials, 2023, The Lancet
  • Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14,324 women in 16 trials, 2023, The Lancet
  • Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis, 2020, JNCI Journal of the National Cancer Institute

The scientist collaborated frequently with several other researchers including Meredith M. Regan, Marco Colleoni, Matteo Benelli, Ilenia Migliaccio, and Luca Malorni.

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    Matthew P. Goetz;Masakazu Toi;Mario Campone;Joohyuk Sohn

  • Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

    Sherene Loi;Nicolas Sirtaine;Fanny Piette;Roberto Salgado

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Bernard Asselain;William Barlow;John Bartlett;Jonas Bergh

  • Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

    Angelo Di Leo;Guy Jerusalem;Lubos Petruzelka;Roberto Torres

  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

    P. A. Francis;P. A. Francis;O. Pagani;G. F. Fleming;B. A. Walley

  • Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

    Angelo Di Leo;Henry L. Gomez;Zeba Aziz;Zanete Zvirbule

  • Dissecting the Heterogeneity of Triple-Negative Breast Cancer

    Otto Metzger-Filho;Andrew M Tutt;Evandro Azambuja;Kamal S Saini

  • MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

    Stephen Johnston;Miguel Martin;Angelo Di Leo;Seock Ah Im

  • Chromogenic in Situ Hybridization: A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples

    Minna Tanner;David Gancberg;Angelo Di Leo;Denis Larsimont

  • Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

    Viviana Galimberti;Bernard F Cole;Giuseppe Viale;Giuseppe Viale;Paolo Veronesi;Paolo Veronesi

  • Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Angelo Di Leo;Stephen Johnston;Keun Seok Lee;Eva Ciruelos

  • HER-2 Amplification and Topoisomerase IIα Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil

    Angelo Di Leo;David Gancberg;Denis Larsimont;Minna Tanner

  • Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

    Sherene Loi;Anita Giobbie-Hurder;Andrea Gombos;Thomas Bachelot

  • Molecular subclasses of breast cancer: How do we define them? The IMPAKT 2012 working group statement

    S. Guiu;S. Michiels;F. André;J. Cortes

  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Richard Gray;Rosie Bradley;Jeremy Braybrooke;Zulian Liu

  • Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.

    Angelo Di Leo;Guy Jerusalem;Lubos Petruzelka;Roberto Torres

  • Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

    Eun Jung Jung;Eun Jung Jung;Libero Santarpia;Juyeon Kim;Francisco J. Esteva

  • Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Ann H. Partridge;R. Bryan Rumble;Lisa A. Carey;Steven E. Come

  • Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications

    Wederson Marcos Claudino;Alessandro Quattrone;Laura Biganzoli;Marta Pestrin

Frequent Co-Authors

Martine Piccart
Martine Piccart Université Libre de Bruxelles
Denis Larsimont
Denis Larsimont Université Libre de Bruxelles
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Giuseppe Viale
Giuseppe Viale University of Milan
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Richard D. Gelber
Richard D. Gelber Harvard University
Evandro de Azambuja
Evandro de Azambuja Université Libre de Bruxelles
Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Meredith M. Regan
Meredith M. Regan Harvard University
Marco Colleoni
Marco Colleoni European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens up a range of related online degree paths and healthcare roles to explore. For those interested in the management side of healthcare, pursuing the best online healthcare administration degree can lead to positions in hospital administration, medical practice management, and policy development.

Registered nurses looking to advance their practice can benefit from specialized adn to fnp bridge programs, enabling them to move efficiently from an associate degree in nursing to a family nurse practitioner role. Nutrition is another rewarding field, and earning an online dietitian degree can open doors in clinical dietetics, sports nutrition, or community health.

For those looking for leadership or executive roles within healthcare systems, consider enrolling in top cahme accredited mha programs to earn a Master of Healthcare Administration. Exploring these online degrees provides greater flexibility and a range of career pathways beyond traditional medical school, helping you find the path that best suits your career aspirations.

Best Scientists Citing Angelo Di Leo

Recently Published Articles